SmallCapsOnline Home





-- Access Pharmaceuticals -- ACTV -- Advanced Tissue Sciences, Inc. -- AMBI Inc. -- ARIAD Pharmaceuticals, Inc. + Initial Opinion -- Cell Therapeutics, Inc. -- CTC Communications -- Cubist Pharmaceuticals, Inc. -- Cypress Bioscience -- CytRx Corp. -- Exigent International, Inc. -- FutureLink Distribution Corp. -- Hemacare Corporation -- Medarex, Inc. -- Valentis, Inc.

To receive immediate notification of research updates, enter your e-mail address here (ex: name@domain.com):

ARIAD PHARMACEUTICALS, INC.

ARIAD Pharmaceuticals has successfully created an integrated program of drug discovery focused on the identification of novel, orally delivered pharmaceuticals based on signal transduction (internal cell communication) technology. ARIA’s "gene-to-drug" platform encompasses its ability to identify and validate new molecular targets (functional genomics), to rationally design drugs that interact with these targets and then to optimize and evaluate the pharmaceutical properties of these drugs (medicinal chemistry and pharmacology). ARIA’s product programs are focused in two areas: 1) the development of small-molecule drugs that block signal transduction pathways that play a critical role in diseases such as osteoporosis, allergy/asthma and immune-related diseases, and 2) the development of orally administered drugs that control the production of therapeutic proteins such as EPO, Human Growth Hormone, Alpha Interferon or Beta Interferon.